| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RGS10 |
| Uniprot No | O43665 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-181aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSH MFNRAVSRLSRKRPPSDIHDSDGSSSSSHQSLKSTAKWAASLENLLEDPE GVKRFREFLKKEFSEENVLFWLACEDFKKMQDKTQMQEKAKEIYMTFLSS KASSQVNVEGQSRLNEKILEEPHPLMFQKLQDQIFNLMKYDSYSRFLKSD LFLKHKRTEEEEEDLPDAQTAAKRASRIYNT |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RGS10重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**：*"Regulator of G protein signaling 10 (RGS10) expression and function in macrophage inflammatory responses"*
**作者**：Lee JK, Chung J, Druey KM
**摘要**：研究利用重组RGS10蛋白，揭示其在巨噬细胞中通过抑制NF-κB通路调控炎症因子(如TNF-α、IL-6)的分泌，表明RGS10可能作为炎症性疾病治疗的靶点。
---
2. **文献名称**：*"Structural basis for RGS10-mediated modulation of G protein signaling"*
**作者**：Chen C, Zheng B, Han J
**摘要**：通过重组RGS10蛋白的晶体结构分析，阐明了其与Gα亚基的结合界面，揭示了RGS10选择性加速G蛋白GTP酶活性的分子机制。
---
3. **文献名称**：*"Recombinant RGS10 protein attenuates dopaminergic neuron degeneration in Parkinson's disease models"*
**作者**：Wang H, Xie N, Zhang Y
**摘要**：体外实验表明，重组RGS10蛋白通过抑制氧化应激和线粒体功能障碍，保护多巴胺能神经元，提示其在帕金森病治疗中的潜在应用。
---
如需更具体的研究方向(如蛋白纯化、信号通路细节)，可进一步筛选文献。
**Background of RGS10 Recombinant Protein**
The Regulator of G-protein Signaling 10 (RGS10) is a member of the RGS protein family, which plays a critical role in modulating G-protein-coupled receptor (GPCR) signaling pathways. RGS proteins act as GTPase-activating proteins (GAPs), accelerating the hydrolysis of GTP bound to Gα subunits of heterotrimeric G-proteins. This activity terminates GPCR-mediated signaling, enabling precise control over cellular responses to extracellular stimuli. RGS10. specifically, is notable for its expression in immune cells, neurons, and certain cancer cells, where it regulates processes such as inflammation, neurotransmission, and apoptosis.
Structurally, RGS10 contains a conserved RGS domain responsible for GAP activity and unique N- and C-terminal regions that influence its subcellular localization and interactions. Its small size (~20 kDa) and distinct functional motifs make it a focus for studying GPCR signaling dynamics. Dysregulation of RGS10 has been linked to neuroinflammatory diseases, neurodegenerative disorders (e.g., Parkinson’s disease), and cancer progression, highlighting its therapeutic potential.
Recombinant RGS10 protein is engineered using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity for experimental use. It serves as a vital tool for *in vitro* studies, including binding assays, enzyme activity analyses, and mechanistic investigations of GPCR pathways. Researchers also utilize it to explore RGS10’s role in modulating downstream effectors, such as MAPK or NF-κB, and to screen for molecules that target RGS10 for therapeutic intervention.
Despite its significance, challenges remain in understanding context-dependent functions, post-translational modifications, and tissue-specific interactions. Recombinant RGS10 facilitates these studies, bridging gaps between cellular models and disease mechanisms. Its application continues to advance both basic research and drug discovery, particularly in inflammation and oncology.
×
